Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084991 | 1.00 | LMNA (0.60) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL1517939 | 1.00 | LMNA (0.60) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL17821267 | 0.93 | LMNA (0.60) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL29028871 | 0.91 | LMNA (0.51) | LMNAALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL30473461 | 0.91 | LMNA (0.51) | LMNAALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL10743911 | 0.90 | LMNA (0.59) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL1245994 | 0.88 | LMNA (0.50) | LMNAALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL3082151 | 0.88 | LMNA (0.50) | LMNAALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL5396950 | 0.88 | LMNA (0.56) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL2084720 | 0.88 | LMNA (0.50) | LMNAALDH1A1GAAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609721-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GEORGETOWN UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-7381745-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1177200-B1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | UNIV GEORGETOWN (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040002478-A1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | NIH - DEITR | 2004-01-01 | — | — | US | disclosed |
| US-6528499-B1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY | 2003-03-04 | — | — | US | disclosed |
| US-6479470-B1 | NAAG AND NAALADASE HAVE BEEN IMPLICATED IN SEVERAL PATHOLOGICAL CONDITIONS RELATING TO GLUTAMATE ABNORMALITIES AND NEUROTOXICITY | GEORGETOWN UNIVERSITY | 2002-11-12 | — | — | US | disclosed |
| WO-2000064911-A9 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | UNIV GEORGETOWN (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002022627-A2 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETWON UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1177200-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETOWN UNIVERSITY (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064911-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETOWN UNIVERSITY (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002478-A1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GRM3, GRM2, GRM1 | LMNA 4788/4885ALDH1A1 1011/4885GAA 191/4885 |
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GRM3, GRM2, GRM1 | LMNA 4788/4885ALDH1A1 1011/4885GAA 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.